Mikhail Kosiborod, MD, cardiologist, Saint Luke’s Mid American Heart Institute and University of Missouri, Kansas City, and coauthor of study titled “Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study,” published in Journal of the American College of Cardiology. Dr. Kasiborod has received research funding and/or served as a consultant to AstraZenica, Boehringer Ingelheim, Janssen and Merck (Diabetes).
Blood-sugar lowering SGLT-2 inhibitor drugs—such as Farxiga, Invokana and Jardiance—treat diabetes and protect your heart at the same time.
